IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Artículos que citan IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Título / Autor	Año
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients V Matson, J Fessler, R Bao, T Chongsuwat, Y Zha, ML Alegre, JJ Luke, ... Science 359 (6371), 104-108	2018
Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, ... JAMA oncology 4 (5), e180013-e180013	2018
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled with targeted next-generation sequencing H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ... Journal of Clinical Oncology 36 (7), 633	2018
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy M Łuksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, ... Nature 551 (7681), 517	2017
Regulation and function of the PD-L1 checkpoint C Sun, R Mezzadra, TN Schumacher Immunity 48 (3), 434-452	2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy R Cristescu, R Mogg, M Ayers, A Albright, E Murphy, J Yearley, X Sher, ... Science 362 (6411), eaar3593	2018
Impact of oncogenic pathways on evasion of antitumour immune responses S Spranger, TF Gajewski Nature Reviews Cancer 18 (3), 139	2018
Emerging concepts for immune checkpoint blockade-based combination therapies R Zappasodi, T Merghoub, JD Wolchok Cancer cell 33 (4), 581-598	2018
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer L Derosa, MD Hellmann, M Spaziano, D Halpenny, M Fidelle, H Rizvi, ... Annals of Oncology 29 (6), 1437-1444	2018
Defining T cell states associated with response to checkpoint immunotherapy in melanoma M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ... Cell 175 (4), 998-1013. e20	2018
Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors KM Hargadon, CE Johnson, CJ Williams International immunopharmacology 62, 29-39	2018
A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, ... Cell 175 (4), 984-997. e24	2018
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response P Jiang, S Gu, D Pan, J Fu, A Sahu, X Hu, Z Li, N Traugh, X Bu, B Li, J Liu, ... Nature medicine, 1	2018
Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study A Necchi, A Anichini, D Raggi, A Briganti, S Massa, R Lucianò, ... Journal of Clinical Oncology 36 (34), 3353-3360	2018
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study G Giaccone, C Kim, J Thompson, C McGuire, B Kallakury, JJ Chahine, ... The Lancet Oncology 19 (3), 347-355	2018
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma CU Blank, EA Rozeman, LF Fanchi, K Sikorska, B van de Wiel, ... Nature medicine 24 (11), 1655	2018
Integrating oncolytic viruses in combination cancer immunotherapy PK Bommareddy, M Shettigar, HL Kaufman Nature Reviews Immunology 18 (8), 498	2018
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 R Mehra, TY Seiwert, S Gupta, J Weiss, I Gluck, JP Eder, B Burtness, ... British journal of cancer, 1	2018
Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma TN Gide, JS Wilmott, RA Scolyer, GV Long Clinical Cancer Research 24 (6), 1260-1270	2018
Converting cold into hot tumors by combining immunotherapies JBAG Haanen Cell 170 (6), 1055-1056	2017

1 - 20

Las fechas y los recuentos de citas son estimados y se determinan de forma automática mediante un programa informático.